KR101626681B1 - 피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도 - Google Patents

피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도 Download PDF

Info

Publication number
KR101626681B1
KR101626681B1 KR1020147000046A KR20147000046A KR101626681B1 KR 101626681 B1 KR101626681 B1 KR 101626681B1 KR 1020147000046 A KR1020147000046 A KR 1020147000046A KR 20147000046 A KR20147000046 A KR 20147000046A KR 101626681 B1 KR101626681 B1 KR 101626681B1
Authority
KR
South Korea
Prior art keywords
methyl
alkyl
formula
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147000046A
Other languages
English (en)
Korean (ko)
Other versions
KR20140019466A (ko
Inventor
크리스토퍼 제이 히랄
토마스 앨런 채피
존 엠 험프리
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20140019466A publication Critical patent/KR20140019466A/ko
Application granted granted Critical
Publication of KR101626681B1 publication Critical patent/KR101626681B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020147000046A 2011-06-07 2012-05-24 피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도 Expired - Fee Related KR101626681B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494070P 2011-06-07 2011-06-07
US61/494,070 2011-06-07
PCT/IB2012/052627 WO2012168817A1 (en) 2011-06-07 2012-05-24 Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors

Publications (2)

Publication Number Publication Date
KR20140019466A KR20140019466A (ko) 2014-02-14
KR101626681B1 true KR101626681B1 (ko) 2016-06-01

Family

ID=46298646

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147000046A Expired - Fee Related KR101626681B1 (ko) 2011-06-07 2012-05-24 피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도

Country Status (11)

Country Link
US (1) US8829010B2 (cg-RX-API-DMAC10.html)
EP (1) EP2718295A1 (cg-RX-API-DMAC10.html)
JP (1) JP2014516074A (cg-RX-API-DMAC10.html)
KR (1) KR101626681B1 (cg-RX-API-DMAC10.html)
CN (1) CN103596956A (cg-RX-API-DMAC10.html)
AU (1) AU2012265970A1 (cg-RX-API-DMAC10.html)
CA (1) CA2836851C (cg-RX-API-DMAC10.html)
IL (1) IL229606A0 (cg-RX-API-DMAC10.html)
MX (1) MX2013014470A (cg-RX-API-DMAC10.html)
SG (1) SG195085A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012168817A1 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2012074951A1 (en) 2010-11-29 2012-06-07 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
WO2014126954A1 (en) * 2013-02-13 2014-08-21 OSI Pharmaceuticals, LLC Regioselective synthesis of substituted pyrimidines
CN104098574A (zh) * 2013-04-12 2014-10-15 苏州科捷生物医药有限公司 氮杂环丁烷取代嘧啶类化合物及其用途
WO2015026646A1 (en) * 2013-08-20 2015-02-26 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 製剤および医薬組成物
EP3134413B1 (en) 2014-04-23 2019-09-11 Dart NeuroScience (Cayman) Ltd. Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學(開曼)有限責任公司 作為pde2抑制劑之經取代的5-甲基-[1,2,4]三唑并[1,5-a]嘧啶-2-胺化合物
BR112017012007B1 (pt) * 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
WO2016090382A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
EP3285581B1 (en) 2015-03-26 2021-08-11 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
EP3291817B1 (en) * 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017000276A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
US10875829B1 (en) 2016-11-18 2020-12-29 Integrative Research Laboratories Sweden Ab Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
US11419874B2 (en) 2017-11-23 2022-08-23 Oslo University Hospital Hf Treatment of tachycardia
CN114805389B (zh) * 2019-11-09 2023-08-29 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN113244395B (zh) * 2020-02-10 2024-07-23 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MX2007008137A (es) * 2005-01-05 2007-07-19 Altana Pharma Ag Triazoloftalazinas como inhibidores de pde2.
WO2006072828A2 (en) 2005-01-07 2006-07-13 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as pde10 inhibitors
CN102020645B (zh) * 2010-09-30 2012-12-12 中山大学 吡唑并嘧啶酮衍生物及其可药用盐、其制备方法和应用

Also Published As

Publication number Publication date
CA2836851A1 (en) 2012-12-13
JP2014516074A (ja) 2014-07-07
AU2012265970A1 (en) 2013-11-28
US8829010B2 (en) 2014-09-09
IL229606A0 (en) 2014-01-30
EP2718295A1 (en) 2014-04-16
WO2012168817A1 (en) 2012-12-13
KR20140019466A (ko) 2014-02-14
SG195085A1 (en) 2013-12-30
MX2013014470A (es) 2014-03-21
CN103596956A (zh) 2014-02-19
CA2836851C (en) 2016-06-21
US20140080806A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
US8829010B2 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors
KR101548443B1 (ko) 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
KR100896380B1 (ko) 헤테로방향족 퀴놀린 화합물 및 pde10 저해제로서의그의 용도
JP2009522346A (ja) Pde10阻害剤としての二環式ヘテロアリール化合物
KR20150027267A (ko) LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
JP2012522027A (ja) 1−複素環−1,5−ジヒドロ−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体及びpde9aモジュレーターとしてのそれらの使用
EA027936B1 (ru) Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)
US20060148809A1 (en) Pyridazine derivatives as ligands for gaba receptors
HUE031831T2 (en) New pyrimidine derivatives having phosphodiesterase 10 inhibitory activity
HK1193814A (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
HK1113926A (en) Heteroaromatic quinoline compounds and their use as pde10 inhibitors
HK1188990A (en) IMIDAZO[5, 1-ƒ][1,2-4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
HK1167263B (en) Heteroaromatic quinoline compounds and their use as pde10 inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190527

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190527

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000